almagate has been researched along with Blindness in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beresniak, A; Bisot-Locard, S; Bremond-Gignac, D; Citterio, T; Cohen, SY; Mimoun, G; Quentel, G | 1 |
| Dobson, R | 1 |
| Giacomelli, G; Menchini, F; Murro, V; Novielli, N; Virgili, G | 1 |
| Del Priore, LV; Shah, AR | 1 |
| Eter, N; Helb, HM; Meyer, CH | 1 |
3 review(s) available for almagate and Blindness
| Article | Year |
|---|---|
Pharmacological treatments for neovascular age-related macular degeneration: can mixed treatment comparison meta-analysis be useful?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Blindness; Combined Modality Therapy; Drug Administration Schedule; Humans; Meta-Analysis as Topic; Photochemotherapy; Photosensitizing Agents; Porphyrins; Ranibizumab; Verteporfin; Wet Macular Degeneration | 2011 |
Progressive visual loss in subfoveal exudation in age-related macular degeneration: a meta-analysis using Lineweaver-Burke plots.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Blindness; Choroidal Neovascularization; Disease Progression; Exudates and Transudates; Humans; Macula Lutea; Macular Degeneration; Photochemotherapy; Pregnadienediols; Randomized Controlled Trials as Topic; Retrospective Studies; Vascular Endothelial Growth Factor A; Visual Acuity | 2007 |
[Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Blindness; Choroidal Neovascularization; Clinical Trials, Phase III as Topic; Fluorescein Angiography; Follow-Up Studies; Humans; Injections; Macular Degeneration; Meta-Analysis as Topic; Monitoring, Physiologic; Multicenter Studies as Topic; Photochemotherapy; Photosensitizing Agents; Porphyrins; Randomized Controlled Trials as Topic; Ranibizumab; Retrospective Studies; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Verteporfin; Vision Tests; Visual Acuity; Vitreous Body | 2008 |
2 other study(ies) available for almagate and Blindness
| Article | Year |
|---|---|
Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Blindness; Computer Simulation; Cost-Benefit Analysis; Decision Trees; Drug Therapy, Combination; Humans; Laser Therapy; Macular Degeneration; Models, Economic; Photosensitizing Agents; Population Surveillance; Porphyrins; Ranibizumab; Treatment Outcome; Verteporfin; Visual Acuity | 2008 |
NICE introduces cost sharing scheme for sight drug.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Blindness; Cost Sharing; Drug Costs; Humans; Ophthalmic Solutions; Ranibizumab | 2008 |